IPM Take
The real shift is not simply that Alzheimer’s has another blood test. It is that diagnosis could start moving closer to primary and secondary care, rather than depending mainly on specialised PET or cerebrospinal fluid pathways. That could shorten diagnostic journeys, but only if systems define who should be tested, how uncertain results are handled and how patients are referred for confirmation, counselling and treatment decisions.
Executive Summary
On 12 May 2026, Roche announced CE mark approval for Elecsys pTau217, a plasma blood test developed with Eli Lilly to help detect Alzheimer’s disease pathology. Roche says the test measures phosphorylated tau 217, an indicator of amyloid pathology, and is intended to help rule in or rule out amyloid pathology in people presenting with symptoms or complaints of cognitive decline. The company states that the same high and low cut-offs can be used across primary and secondary care settings, and that the test should be used alongside other clinical information rather than as a standalone diagnosis.
Why it matters
- Diagnostics / pathology: Need validated laboratory workflows, quality control and reporting standards so blood biomarker results are clinically usable.
- Clinicians: Must define which symptomatic patients should be tested, how to manage intermediate results and when confirmatory testing is needed.
- Patients / advocates: Should watch whether easier testing shortens diagnostic delay without creating confusion, over-testing or unsupported results.
Previously, confirmation of Alzheimer’s pathology often depended on specialist access to PET imaging or cerebrospinal fluid testing. Those pathways can be expensive, invasive, slow or unevenly available, especially outside major memory centres.
What has changed is the movement of blood-based biomarkers toward routine diagnostic workflows. Elecsys pTau217 is intended for people with symptoms or complaints of cognitive decline, not for general population screening. A high result is intended to support a high likelihood of amyloid pathology, a low result can help rule it out, and intermediate results require additional assessment.
The implementation issue is practical. Easier blood testing may increase demand for memory services, confirmatory testing and counselling. Health systems will need clear referral criteria, laboratory capacity, clinician education and pathways for patients who may be eligible for disease-modifying therapies.
For IPM, the message is direct: Alzheimer’s blood tests can improve access only if they are embedded in a safe diagnostic pathway. A faster test is valuable when it leads to timely confirmation, informed counselling and appropriate care decisions.
